Waljee AK, et al. - Researchers performed this study to enable physicians, patients, and insurers to predict whether a patient with ulcerative colitis (UC) would respond to vedolizumab at an early time point after starting therapy. Using laboratory data through week 6 of vedolizumab therapy, a machine learning algorithm was able to accurately identify which UC patients would achieve corticosteroid-free endoscopic remission on vedolizumab at week 52. When the benefits of the vedolizumab were not clinically apparent in the first 6 weeks of therapy, application of this algorithm could have significant implications for clinical decisions on whom to continue on this costly medication.